对选择性,共价的JNK2/3抑制剂的"联体先"方法
Valentin R Wydra1, Nicole Plank2, Stefan Zwirner3
1Department of Pharmaceutical/Medicinal Chemistry, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, DE, Germany.
研究人员开发了新的JNK2/3选择性抑制剂. 这些化合物,无论是可逆的还是共价的,都显示出高强度和细胞活性,而共价化合物显示出出色的动力和选择性概况.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- JNK异型 (JNK1,JNK2,JNK3) 在疾病中起着不同的作用.
- 与JNK1和JNK3相比,JNK2的研究较少.
- JNK3是神经退行性疾病的目标,而JNK1抑制剂正在临床试验中.
研究的目的:
- 开发新型,高强度和同型选择性JNK2/3抑制剂.
- 探索可逆和共价抑制剂的策略.
- 为了识别具有有利的动力和选择性特性的化合物.
主要方法:
- 一个aminopyrazole脚手架的结构引导优化.
- 对抑制剂设计的代性联结体-第一方法.
- 将可逆抑制剂转化为共价抑制剂,使用电友性弹头准保存的氨酸.
主要成果:
- 产生新的,强大的JNK2/3选择性可逆和共价抑制剂.
- 对于这两种抑制剂类型,已表现出高的异形选择性和细胞活性.
- 共价化合物56d表现出强烈的抑制 (k_inact/K_I = 38,200 M^-1 s^-1对于JNK2),细胞选择性,以及一个干净的基因组概况.
结论:
- 通过结构导向方法成功开发出强效和选择性的JNK2/3抑制剂.
- 化抑制剂向保存的囊蛋白,是抑制JNK2/3的一个有希望的策略.
- 化合物56d显示出进一步治疗开发的潜力,特别是涉及JNK2/3失调的疾病.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
The JAK-STAT Signaling Pathway
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Amplifying Signals via Enzymatic Cascade
Ligand Binding and Linkage
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
